GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaron Beijing Co Ltd (SZSE:300759) » Definitions » Piotroski F-Score

Pharmaron Beijing Co (SZSE:300759) Piotroski F-Score : 4 (As of May. 26, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Pharmaron Beijing Co Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Pharmaron Beijing Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Pharmaron Beijing Co's Piotroski F-Score or its related term are showing as below:

SZSE:300759' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 8
Current: 4

During the past 10 years, the highest Piotroski F-Score of Pharmaron Beijing Co was 8. The lowest was 3. And the median was 6.


Pharmaron Beijing Co Piotroski F-Score Historical Data

The historical data trend for Pharmaron Beijing Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaron Beijing Co Piotroski F-Score Chart

Pharmaron Beijing Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.00 6.00 6.00 6.00 6.00

Pharmaron Beijing Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 7.00 7.00 6.00 4.00

Competitive Comparison of Pharmaron Beijing Co's Piotroski F-Score

For the Biotechnology subindustry, Pharmaron Beijing Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmaron Beijing Co's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmaron Beijing Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Pharmaron Beijing Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was 437.838 + 352.945 + 462.058 + 230.558 = ¥1,483 Mil.
Cash Flow from Operations was 750.065 + 749.198 + 724.136 + 745.631 = ¥2,969 Mil.
Revenue was 2916.147 + 2920.139 + 2977.739 + 2670.741 = ¥11,485 Mil.
Gross Profit was 1074.13 + 1028.808 + 1046.58 + 872.149 = ¥4,022 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(21047.569 + 22390.082 + 22476.013 + 26476.713 + 25243.967) / 5 = ¥23526.8688 Mil.
Total Assets at the begining of this year (Mar23) was ¥21,048 Mil.
Long-Term Debt & Capital Lease Obligation was ¥7,388 Mil.
Total Current Assets was ¥9,448 Mil.
Total Current Liabilities was ¥3,756 Mil.
Net Income was 336.346 + 375.675 + 413.497 + 348.255 = ¥1,474 Mil.

Revenue was 2531.686 + 2768.209 + 2863.494 + 2723.971 = ¥10,887 Mil.
Gross Profit was 927.003 + 1078.445 + 1067.322 + 974.966 = ¥4,048 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(18660.921 + 18966.871 + 19706.905 + 20492.557 + 21047.569) / 5 = ¥19774.9646 Mil.
Total Assets at the begining of last year (Mar22) was ¥18,661 Mil.
Long-Term Debt & Capital Lease Obligation was ¥5,229 Mil.
Total Current Assets was ¥6,559 Mil.
Total Current Liabilities was ¥3,935 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Pharmaron Beijing Co's current Net Income (TTM) was 1,483. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Pharmaron Beijing Co's current Cash Flow from Operations (TTM) was 2,969. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=1483.399/21047.569
=0.0704784

ROA (Last Year)=Net Income/Total Assets (Mar22)
=1473.773/18660.921
=0.07897643

Pharmaron Beijing Co's return on assets of this year was 0.0704784. Pharmaron Beijing Co's return on assets of last year was 0.07897643. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Pharmaron Beijing Co's current Net Income (TTM) was 1,483. Pharmaron Beijing Co's current Cash Flow from Operations (TTM) was 2,969. ==> 2,969 > 1,483 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=7388.346/23526.8688
=0.31403865

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=5228.557/19774.9646
=0.26440285

Pharmaron Beijing Co's gearing of this year was 0.31403865. Pharmaron Beijing Co's gearing of last year was 0.26440285. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=9448.379/3756.103
=2.51547388

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=6558.584/3934.762
=1.66683118

Pharmaron Beijing Co's current ratio of this year was 2.51547388. Pharmaron Beijing Co's current ratio of last year was 1.66683118. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Pharmaron Beijing Co's number of shares in issue this year was 1776.255. Pharmaron Beijing Co's number of shares in issue last year was 1770.49. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=4021.667/11484.766
=0.35017405

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=4047.736/10887.36
=0.37178306

Pharmaron Beijing Co's gross margin of this year was 0.35017405. Pharmaron Beijing Co's gross margin of last year was 0.37178306. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=11484.766/21047.569
=0.5456576

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=10887.36/18660.921
=0.58343101

Pharmaron Beijing Co's asset turnover of this year was 0.5456576. Pharmaron Beijing Co's asset turnover of last year was 0.58343101. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+0+1+0+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Pharmaron Beijing Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Pharmaron Beijing Co  (SZSE:300759) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Pharmaron Beijing Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Pharmaron Beijing Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmaron Beijing Co (SZSE:300759) Business Description

Traded in Other Exchanges
Address
No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Hong Kong, HKG
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services; Clinical development services and biologics and CGT services. The company generates maximum revenue from Laboratory services segment.
Executives
Lou Xiao Qiang Directors, executives
Zheng Bei Directors, executives

Pharmaron Beijing Co (SZSE:300759) Headlines

No Headlines